Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Aisin focuses on offshore development services, make a website, T engineer introduction, dispatch, Chinese translation, and analysis, design, and development of the system. The company aim to be lovingly engaged in their work and treated sincerely with customers and trusted. Aisin was founded on July 10, 2015, and is based in Tokyo, Japan.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

The latest news, sports and events from Northern Illinois University.

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Shandong Tanzhen Biotechnology Co., Ltd., established on 2016-02-18, Business scope includes biotechnology extension services;Research and development of biological products,Production,Sales;medical instruments,Sales of instrumentation,lease;electronic product,Electronic Component,plastic products,Packaging Materials,Chemical Products(None of the above two items contain hazardous chemicals)promotion of;computer information technology research and development,technical consulting,Technical Services;Import and export business of goods and technology(Except for businesses that are restricted by the state or prohibited from import and export);Self-owned commercial housing rental service;Self-owned housing rental service.(Projects approved by law,Business activities can only be carried out after approval by relevant departments)

Promab Biotechnologies, Inc. is a private company headquartered in Richmond, CA, that develops and commercializes recombinant proteins & custom monoclonal antibodies. The firm was founded by Jim Howell Qian.\nThe company says this about itself: ProMab has been an expert in the antibody development field for 19 years, and has been steadily introducing innovative CAR-T/NK cell technology platforms to serve our clients in the immuno-oncology field. The company aims to out-license antibodies validated in CAR-T cell technology in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study. ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of CAR-T/NK cell for life science and biologics development. ProMab offers licenses to its existing antibodies and CAR-T/NK cell platform IP in multiple fields of immuno-oncology.

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Biosense Laboratories AS supplies products and test systems for detecting and analyzing xenobiotics. Its products include Vitellogenin (Vtg) ELISA kits, Biomarker Abs/Stds, Plant Pathogen Tests, and Biochemical Research. The company was founded by Anders Goksoyr in 1996 and is headquartered in Bergen, Norway.

Kirin Brewery Co., Ltd. engages in the manufacture of alcoholic beverages. Its products include beer, sparkling liquor, chuhai, gin, and whiskey. The company was founded in 1901 and is headquartered in Tokyo, Japan.

Warner Chilcott Co., Inc. develops, manufactures and markets branded prescription pharmaceutical products. The company is located in Rockaway, NJ

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

Ezaki Glico Co. is a food company headquartered in Osaka, Japan. It has 11 business locations and 23 group companies in Japan, and 12 subsidiaries in nine countries. Ezaki Glico operates a total of 19 plants and has 5,210 employees all over the world. Since the launch in 1922 of the nutritious and fortified Glico caramel in its distinctive red box, the business activities of Ezaki Glico have adhered to the corporate philosophy of "Enhancing Public Health Through Food." Upon the 70th anniversary of Ezaki Glico in 1992, this same spirit and dedication have been incorporated into the revised corporate philosophy of "A Wholesome Life in the Best of Taste." Glico caramel – the company's first product – incorporates the innovative creativeness of Mr. Riichi Ezaki, the company's founder. From the beginning, all personnel working for the company have been dedicated to further enhancing people's health and quality of life. This has led to the expansion of business lines beyond confectionery to include ice cream products, processed foods, desserts, milk products, baby formula, food ingredients, and ingredients for cosmetic and health products.

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. By bringing together scientists from many disciplines, the Crick will help to improve people's lives and keep the UK at the forefront of innovation in medical research, attracting high-value investment and strengthening the economy.

Hunan ProMab Biotechnologies Co. Ltd., a subsidiary of Shanghai Shineton Investment Co., Ltd., is a Chinese company that engages in research and development of biological products. It was acquired by Shanghai Shineton Investment Co., Ltd. from NanHua Bio-medicine Co., Ltd. on December 21, 2019 for $13.75 million.